Skip to main content
      RT @RichardPAConway: Daniela Ospina Cardona presenting at the Down and Dirty 30 on VEXAS. Marked differences in mortalit

      Richard Conway RichardPAConway

      4 years ago
      Daniela Ospina Cardona presenting at the Down and Dirty 30 on VEXAS. Marked differences in mortality depending on exact mutation. Looking forward to hearing more about this at Plenary session III today #ACR21 @RheumNow https://t.co/R3gXpxOfSk
      RT @drdavidliew: Baricitinib for *relapsing* GCA (Th1+Th17)
      w abbreviated steroid wean (15-22w)

      Despite being tougher t

      David Liew drdavidliew

      4 years ago
      Baricitinib for *relapsing* GCA (Th1+Th17) w abbreviated steroid wean (15-22w) Despite being tougher to treat: 100% off steroids at 24w 93% off steroids at 52w no ischemic Sx promising as another GCA Rx option! (post-cessation 4pts flared) @MayoClinic #ACR21 ABST1396 @RheumNow https://t.co/dqFnHQYogk
      RT @AurelieRheumo: It is #ACR21, but it is also #COP26Glasgow 🌎! What can we do for climate as physicians? "Our job i

      Aurelie Najm AurelieRheumo

      4 years ago
      It is #ACR21, but it is also #COP26Glasgow 🌎! What can we do for climate as physicians? "Our job is to make changes" Strong message for #ClimateAction from Dr Paul Dellaripa during his talk at the climate, pollution and IRMDs study group session @RheumNow https://t.co/GWxpzYD3lg
      RT @drdavidliew: "GCA is not a single, monolithic disease"
      - Christian Dejaco, rightfully asking why we don't stratify t

      David Liew drdavidliew

      4 years ago
      "GCA is not a single, monolithic disease" - Christian Dejaco, rightfully asking why we don't stratify treatment/trials in GCA #ACR21 PMR/GCA Study Group @RheumNow @Sarah_L_Mackie @profbdasgupta @EBRheum @RichardPAConway @SattuiSEMD @drceowen
      Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis. With multiple JAK inhibitors available in the United States (tofacitinib, baricitinib, and upadacitinib), patients who fail one treatment option have the ability to switch to another agent or change to biologic therapy. 
      RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All

      Dr. John Cush RheumNow

      4 years ago
      RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow and its Faculty.
      The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
      RT @ericdeinmd: #ACR21 Abs#0819. RheumTAP real-world cohort of pts tapering Rx in remission on RA
      ▶️ Pts tapering 7.

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abs#0819. RheumTAP real-world cohort of pts tapering Rx in remission on RA ▶️ Pts tapering 7.6x ⬆️ likely to flare in f/u Great convo soon on @Rheumnow re: tapering studies. @davidliew asks how many more times do we need to see drug w/d fail? https://t.co/BiZSM7yp7o https://t.co/iDXGVpFZzB
      RT @ericdeinmd: #ACR21 Rheum Pearls and Secrets
      Not all (or most) ulcers is Behcet's! Here's a great approach to use in

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Rheum Pearls and Secrets Not all (or most) ulcers is Behcet's! Here's a great approach to use in clinic. Jason Kolfenbach: "Sometimes, taking off the mask is worth it" @Rheumnow https://t.co/OEBgf1eFhd
      ×